9.09 USD
▲-0.06+0.44%
盘后 9.04 -0.11%
2026-08-03
市值
$54.38M
市盈率
—
EPS
-5.41
股息率
—
52 周区间
6.47 – 12.74
成交量
20.54K
Beta
-0.12
目标价
—
52W 低 6.4752W 高 12.74
价格走势
公司简介
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in...